Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estetrol/Drospirenone to Reduce the Average Size of Endometriomas
NCT05837624Phase 4Recruiting
- Start
- Dec 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of estetrol + drospirenone in ovarian endometrioma. Primary endpoint: Change in ovarian endometrioma volume at 6 months. Started Dec 2024; status: recruiting.
02
Drugs
estetrol + drospirenone
03
Conditions
ovarian endometrioma
Beyond the preview
Go deeper on NCT05837624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05837624.